| Literature DB >> 23191987 |
Weifeng Shi1, Xiang Li, Xueling Hou, Hongjun Peng, Qingbo Jiang, Mei Shi, Yun Ji, Xiping Liu, Jinbo Liu.
Abstract
BACKGROUND: Enterovirus 71 (EV71) infection can induce the apoptosis of infected cells. The aim of this study is to explore the effect of EV71 infection on apoptosis mechanisms in virus-infected human rhabdomyosarcoma (RD) cells.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23191987 PMCID: PMC3536580 DOI: 10.1186/1471-2334-12-327
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Figure 1The characteristics of EV71-infected RD cell proliferation in different time points. Control: Uninfected RD cells. Mock: Inactivated EV71-infected RD cells. EV71: EV71-infected RD cells. Viable cell count was assessed by trypan blue exclusion technique. The data were expressed as mean ± SE from 3 independent experiments. * P < 0.05 and **P < 0.01 by two-way ANOVA.
Figure 2The morphology of EV71-infected RD cells. Following the infection at 8 and 20 h in RD cells, cell morphology was examined under a light microscope (100×), and visible cell apoptosis was labeled by black arrow.
Figure 3EV71-induced apoptosis in RD cells. Early membrane revealed an obvious change associated with apoptosis in EV71-infected RD cells. The exposure of phosphatidylserine (PS) was analyzed using FITC-labeled annexin V. Cell death was assessed with propidium iodide (PI). EV71-infected RD cells were harvested at 20 and 32 h postinfection and stained with annexin V-FITC/PI, and then observed under a fluorescence microscope (400×).
Figure 4Membrane changes associated with apoptosis in EV71-infected RD cells. Control: Uninfected RD cells. EV71: EV71-infected RD cells. The exposure of phosphatidylserine (PS) was analyzed using FITC-labeled annexin V. Cell death was assessed using PI in a time course mode. EV71-infected RD cells were harvested at 8 and 20 h postinfection and cell death was evaluated by flow cytometry.
Figure 5EV71 infection activates the release of cytokines in RD cells. The culture supernatants of control, mock and EV71-infected RD cells were harvested at 0, 8, 20 and 32 h after infection to measure the cytokines by ELISA. The data were expressed as mean ± SE of 3 independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 by two-way ANOVA.
Figure 6PCR amplification and melting curves. Uninfected Control: A, B and E, F; amplification curves and melting curves at 8 and 20 h, respecively. EV71-infected RD cells: C, D and G, H; amplification curves and melting curves at 8 and 20 h postinfection by EV71, respecively.
Differential apoptotic gene expressions of RD cells in response to EV71 infection at 8 and 20 h postinfection
| | | ||
|---|---|---|---|
| ACIN1 | Apoptotic chromatin condensation inducer 1 (ACINUS; ACN; fSAP152) | -3.17 | 1.33 |
| AIFM1 | Apoptosis-inducing factor 1 (AIF; COXPD6; PDCD8) | 1.03 | -1.33 |
| AIFM2 | Apoptosis-inducing factor, mitochondrion-associated, 2 (AMID; PRG3; RP11-367H5.2) | -3.83 | -1.25 |
| Akt1 | V-akt murine thymoma viral oncogene homolog 1 (AKT1; PKB; PKB-ALPHA; PRKBA; RAC; RAC-ALPHA) | -9.89 | -1.13 |
| Akt2 | V-akt murine thymoma viral oncogene homolog 2 (AKT2, PKBB; PKBBETA; PRKBB; RAC-BETA) | -3.36 | 2.66 |
| Akt3 | V-akt murine thymoma viral oncogene homolog 3(AKT3) | -1.06 | 1.58 |
| APAF1 | Apoptotic peptidase activating factor 1 (APAF-1; CED4) | -4.10 | 1.09 |
| API5 | Apoptosis inhibitor 5 (AAC-11; AAC11) | -5.41 | 1.06 |
| Bcl-2 | B-cell lymphoma 2 (BCL-2) | -1.07 | -1.43 |
| BIRC2 | Baculoviral IAP repeat-containing 2 | 1.56 | 1.23 |
| BIRC3 | Baculoviral IAP repeat-containing 3 (AIP1; API2; CIAP2; HAIP1; HIAP1; MALT2; MIHC; RNF49; c-IAP2) | -1.84 | 3.19 |
| Caspase-3 | Apoptosis-related cysteine peptidase 3(Casp3) | 1.91 | 2.38 |
| Caspase-4 | Apoptosis-related cysteine peptidase 4(Casp4) | -1.31 | 1.15 |
| Caspase-7 | Apoptosis-related cysteine peptidase 7(Casp7) | -2.15 | 2.03 |
| Caspase-8 | Apoptosis-related cysteine peptidase 8(Casp8) | 1.87 | 2.17 |
| Caspase-9 | Apoptosis-related cysteine peptidase 9(Casp9) | -4.98 | -1.02 |
| Caspase-10 | Apoptosis-related cysteine peptidase 10(Casp10) | 1.25 | 2.16 |
| Caspase-12 | Apoptosis-related cysteine peptidase 12 (Casp12) | 1.24 | 1.10 |
| CD5 | CD5 molecule | -2.41 | 4.77 |
| CD70 | CD70 molecule | 1.55 | 4.04 |
| CD40L | CD40 ligand | -2.51 | 5.44 |
| CD24 | CD24 molecule | 1.53 | 2.98 |
| CD27 | CD27 molecule | -2.37 | 1.71 |
| c-Fos | c-fos proto-oncogene | 2.34 | 3.23 |
| c-Jun | c-Jun proto-oncogene | 1.69 | 5.52 |
| CIDEA | Cell death-inducing DFFA-like effector a | -1.32 | -1.58 |
| CIDEB | Cell death-inducing DFFA-like effector b | -2.67 | 2.98 |
| DAPK1 | Death-associated protein kinase 1 | -2.80 | 1.24 |
| DAPK2 | Death-associated protein kinase 2 | -1.81 | 1.32 |
| DAPK3 | Death-associated protein kinase 3 (ZIP; ZIPK) | -10.17 | 2.06 |
| DFFA | DNA fragmentation factor subunit alpha (DFF-45; DFF1; ICAD) | -2.09 | -1.14 |
| E2F1 | Transcription factor E2F1 (RBAP1; RBBP3; RBP3) | -3.99 | -1.17 |
| E2F2 | Transcription factor E2F2 | -1.64 | 1.55 |
| EGFR | Epidermal growth factor receptor | -4.78 | 1.38 |
| ENDOG | Endonuclease G | -11.37 | 1.06 |
| ERBB3 | Receptor tyrosine-protein kinase erbB-3 (ErbB-3; HER3; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3) | -2.29 | 1.54 |
| FADD | Fas-associated protein with death domain (MORT1) | -1.48 | -1.42 |
| FasL | Fas ligand (FAS L, CD95L; CD178; TNFSF6) | -1.14 | 7.53 |
| Fas | Fas receptor (ALPS1A; APO-1; APT1; CD95; FAS1; FASTM; TNFRSF6) | -1.23 | 3.26 |
| IFN-α2 | Interferon alpha-2 | 1.13 | 1.54 |
| IFN-β1 | Interferon beta | 5.22 | 1.47 |
| IGF1 | Insulin-like growth factor 1 (IGF-I; IGF1A; IGFI) | -1.14 | -1.15 |
| IGF1 R | Insulin-like Growth Factor 1 (IGF-1), Receptor (CD221; IGFIR; IGFR; JTK13) | -3.50 | 1.27 |
| IKBKB | inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-beta; IKK2; IKKB; NF-κBIKB) | -3.52 | 1.33 |
| IKBKG | inhibitor of nuclear factor kappa-B kinase subunit gamma (AMCBX1; FIP3; IKK-gamma; IP1; IP2; IPD2; NEMO) | -5.76 | 1.40 |
| IL-10 | Interleukin 10 | 1.10 | 12.15 |
| IL-1α | Interleukin-1 alpha | -2.60 | 1.64 |
| IL-1β | Interleukin-1 beta | -2.20 | 1.30 |
| IL-2 | Interleukin 2 | 1.24 | 12.15 |
| IL-4 | Interleukin 4 | -3.72 | 2.39 |
| IL-6R | Interleukin 6 receptor (CD126) | -5.80 | 1.92 |
| IL-7 | Interleukin 7 | -1.65 | 1.26 |
| IRAK1 | Interleukin-1 receptor-associated kinase 1 | -3.70 | 3.39 |
| JAK2 | Janus kinase 2 (JTK10; THCYT3) | 1.06 | -1.21 |
| MAP3K1 | Mitogen-activated protein kinase kinase kinase 1 (MAPKKK1; MEKK; MEKK 1; MEKK1; SRXY6) | -4.55 | 1.51 |
| MAP3K5 | Mitogen-activated protein kinase kinase kinase 5 (ASK1; MAPKKK5; MEKK5) | -2.39 | 1.99 |
| MAP2K4 | Mitogen-activated protein kinase kinase 4 (JNKK1; MAPKK4; MEK4) | -1.06 | 2.54 |
| MAP2K7 | Mitogen-activated protein kinase kinase 7(MAPKK7; MEK7) | -1.09 | 3.05 |
| MAPK1 | Mitogen-activated protein kinase 1 (ERK; ERK2; ERT1; MAPK2; P42MAPK; PRKM1; PRKM2; p38; p40; p41) | -2.21 | 1.00 |
| MAPK3 | Mitogen-activated protein kinase 3(ERK1; HS44KDAP; P44ERK1; P44MAPK; PRKM3; p44-ERK1; p44-MAPK) | -2.74 | 1.67 |
| MAPK8 | Mitogen-activated protein kinase 8(JNK; JNK1; SAPK1) | 1.73 | 2.53 |
| MAPK9 | Mitogen-activated protein kinase 9(JNK2; JNK2A; JNK2B; SAPK) | 1.02 | 2.25 |
| MYD88 | Myeloid differentiation primary response gene (88) | -6.09 | 1.82 |
| NF-κB1 | Nuclear factor NF-kappa-B p105 subunit(NFKB-p105; NFKB-p50; NFkappaB; p105; p50) | -4.81 | 1.18 |
| NF-κB3 | Transcription factor p65 (RELA; NF-κB p65) | -1.35 | 2.63 |
| NF-κBIA | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IKBA; MAD-3; NFKBI) | 1.49 | 2.96 |
| NTRK1 | Neurotrophic tyrosine kinase receptor type 1(MTC; TRK; TRK1; TRKA; Trk-A; p140-TrkA) | -2.84 | 1.33 |
| PDCD1 | Programmed cell death protein 1( CD279; PD-1; hPD-l) | -1.63 | 4.48 |
| PDCD4 | Programmed cell death protein 4 | -1.30 | 1.06 |
| PDCD 7 | Programmed cell death protein 7 | 1.87 | 1.42 |
| PI3K-α | Phosphoinositide-3-kinase, catalytic, alpha polypeptide(PIK3CA; p110-alpha; PI3K) | -1.26 | 1.04 |
| PI3K-γ | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG ; PI3K; PI3Kgamma; PIK3) | -1.40 | 5.18 |
| PIK3R2 | Phosphatidylinositol 3-kinase regulatory subunit beta(P85B; p85; p85-BETA) | -2.12 | -1.20 |
| PPP3R1 | protein phosphatase 2B regulatory subunit 1(CALNB1; CNB; CNB1) | -1.52 | 1.94 |
| RIPK1 | Receptor-interacting serine/threonine-protein kinase 1(RIP; RIP1) | -2.44 | 1.24 |
| STAT1 | Signal transducers and activators of transcription (CANDF7; ISGF-3; STAT91) | -6.18 | 4.04 |
| STAT5A | Signal transducer and activator of transcription 5A | -1.14 | -1.15 |
| STAT5B | Signal transducer and activator of transcription 5B | -3.17 | 1.08 |
| TGFB1 | Transforming growth factor beta 1(CED; DPD1; LAP; TGFB; TGFbeta) | -2.23 | -1.15 |
| TNF-α | Tumor necrosis factors | -1.97 | 2.19 |
| TNFRSF10A | Tumor necrosis factor receptor superfamily member 10A (APO2; CD261; DR4; TRAILR-1; TRAILR1) | -2.82 | 2.03 |
| TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B (DR5, CD262, TRICK2, TRICKB, TRAILR2, TRICK2A, TRICK2B) | -2.84 | 1.02 |
| P53 | Tumor protein 53(LFS1; TP53; TRP53) | -7.60 | 1.32 |
| XIAP | X-linked inhibitor of apoptosis protein(API3; BIRC4; IAP-3; ILP1; MIHA; XLP2; hIAP3) | -1.94 | 2.59 |
Negative values indicate down-regulation of genes.
Figure 7EV71 infection induced activation of apoptotic signal pathway proteins. Cell lysates were prepared from EV71-infected RD cells at the indicated time and resolved with 12% SDS-PAGE. Proteins were transferred onto PVDF membranes and subjected to western blotting. (A) FasL expression in EV71- infected RD cells at 0, 8, and 20 h. (B) Western blot analysis for caspase-10, -8, -7, and -3 in EV71- infected RD cells at 0, 3, 8, 20 and 24 h. GAPDH was probed as the loading control. The phosphorylated or total proteins of AKT2 (C), JNK1/2 (D), NF-κB (E) and c-Jun (F) were detected by western blotting at 0, 8, and 20 h. The amounts of β-actin were also assessed to monitor the equal loadings of protein extracts.
Figure 8Putative apoptotic pathways in EV71-infected RD cells. The pathways were deduced from PCR array and western blotting analysis.